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a b s t r a c t
Introduction: Human platelet lysate (hPL) part of the growth factor cocktail derived from human
platelets, which has been applied as a cell growth supplement. The production process is easier in
comparison to platelet-rich plasma; thus, hPL is now considered for use in wound healing therapy.
However, methods for preserving hPL for more than several months that maintain its bioactivity must be
considered, especially for chronic wound treatment. The present study compared the effects of preser-
vation for 9 months using a refrigerator or deep freezer.
Methods: We investigated three preservation conditions. In the C-hPL group, hPL was stored at 80 C in
a deep freezer for 9 months; in the CL-hPL group, hPL was cryopreserved for 9 months at 80 C in a
deep freezer then lyophilized; in the L-hPL group, lyophilized hPL was refrigerated at 4 C for 9 months.
The quantity and quality of growth factors in these three groups were measured by an ELISA and in
fibroblast cell cultures. Then, gelatin hydrogel discs were impregnated with hPL and its effects with
regard to the promotion of wound healing in mice were evaluated by histologic examinations.
Results: The PDGF-BB concentration in C-hPL, CL-hPL and L-hPL was 18,363 ± 370 pg/ml, 11,325 ± 171 pg/
ml, and 12,307 ± 348 pg/ml, respectively; the VEGF concentration was 655 ± 23 pg/ml, 454 ± 27 pg/ml,
and 499 ± 23 pg/ml, respectively; and the TGF-b1 concentration was 97,363 ± 5418 pg/ml,
73,198 ± 2442 pg/ml, and 78,034 ± 3885 pg/ml, respectively. In cell culture medium, fibroblast cell
cultures were better supported in the hPL groups than in the fetal bovine serum group. In the histologic
examination of the wound healing process, no differences were observed among the three preserved hPL
groups with regard to epithelialization, or granulation tissue or capillary formation. The wounds in all
groups had almost healed by day 14.
Conclusions: The stability of growth factors contained in lyophilized hPL is maintained at 4 C for up to
9 months. This was a versatile preservation method that can be applied in clinical practice.
© 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Platelets are anucleated cells containing many types of growth
factors, including platelet-derived growth factor (PDGF), trans-
forming growth factor b (TGF-b), vascular endothelial growth factor
(VEGF) and epidermal growth factor (EGF) in these alpha granules
[1,2]. Platelets play an important role in the beginning of thewound
healing process. At the hemostasis phase, platelets are aggregated
and activated to form a blood clot through binding to fibrinogen
and to prevent blood loss at the injury site. At the same time, these
growth factors are released from platelets and play an important
role in the initiation of the wound repair process [3e5]. These
growth factors from platelets have been used as cell growth sup-
plements or clinical treatments for wound healing. Platelet-rich
plasma (PRP) has commonly been used in clinical practice and is
usually obtained from the patient's autologous blood [1,6,7]. Hu-
man platelet lysate (hPL) is a cocktail of growth factors prepared
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from donated human platelets and has mainly been used in in vitro
experiments as a supplement for cell culture [8e12].
Chronic skin wounds, such as diabetic ulcers, pressure ulcers,
venous leg ulcers, currently represent a major healthcare burden
for both professionals and patients. The long healing process is
associated with high treatment costs, prolonged hospital stays, and
affects the patient's quality of life. We are investigating the use of
platelets and platelet-derived growth factors in the treatment
chronic wounds, and have reported that PRP promotes the prolif-
eration of human adipose-derived stem cells and human dermal
fibroblasts [13,14], and that PRP has an angiogenic effect on human
umbilical vein endothelial cells (HUVECs) [15]. We also reported
that we could preserve lyophilized autologous PRP by refrigeration
at 4 C and that refrigerated lyophilized PRP could be safely used in
the clinical setting [16]. As for hPL, we applied a collagen/gelatin
scaffold impregnated with various concentrations of lyophilized
hPL from expired irradiated platelet concentrate to a murine
wound healing model and showed its healing effects [9].
As mentioned above, in previous studies, we used a lyophiliza-
tion technique to preserve PRP or regulated the concentrations of
hPL, we have not evaluated the effective storage period, for which
the bioactivity of hPL is maintained. The healing of chronic ulcers
usually takes several months; thus, methods that can preserve PRP
or hPL for more than several months, which also preserve its
bioactivity, are required. For short-term preservation for periods of
less than 1 month, bioactive substances can be preserved at 4 C;
however, for longer preservation, cryopreservation using liquid ni-
trogen, or at20 C or80 C using a deep freezer is recommended
[17,18]. On the other hand, it has been reported that lyophilized
proteins can be stored at 4 C or room temperature for longer pe-
riods of time [19e21]. In clinical practice, refrigeration at 4 Cwould
be desirable because a deep freezers are not installed in many
hospitals and are associated with additional costs.
In the present study, we compared different methods for pre-
serving hPL using a refrigerator or deep freezer. We set the pres-
ervation period of 9 months, the wound healing process for chronic
wounds usually takes more than 6 months. We evaluated the
bioactivity of preserved hPL in vitro and later in vivo using a murine
wound healing model.
2. Materials and methods
2.1. Preparation of gelatin hydrogel (GH) sheets
Weused gelatin hydrogel (GH) sheets in the animal experiments.
GH sheets are bioabsorbable dressings that can sustain the release
of bFGF (basicfibroblast growth factor) or PDGF-BB (platelet derived
growth factor-BB) and we reported that GH sheets impregnated
with PRPr (platelet-rich plasma releasate) accelerated murine
wound healing [6]. GH sheets were prepared by the Department of
Regeneration Science and Engineering Laboratory of Biomaterials,
Institute for Frontier Medical Sciences, Kyoto University. In brief,
acidic gelatin, with an isoelectric point of 5.0, isolated from bovine
bone (Nitta Gelatin Co., Osaka, Japan) was used [6,22]. Gelatin in 5%
(w/v) aqueous solutionwasfirst cross-linkedwith glutaraldehyde at
4 C for 12 h in polystyrene dishes. Then, the resulting hydrogel
sheets were immersed in a glycine aqueous solution at 37 C for 1 h
to block the residual aldehyde. The hydrogel sheets were then
rinsed with double-distilled water (DDW) then lyophilized. The
dried hydrogels were sterilized with ethylene oxide gas.
2.2. Preparation and preservation of hPL
This study used 200 ml of expired irradiated platelet concen-
trate, leukocyte reduced (Ir-PC-LR) (Japanese Red Cross Society)
that was supplied by Kansai Medical University Hospital at the
expiration date. Our experiment protocol was approved by the
ethics committee of Kansai Medical University (approval No. 1427).
At first, the Ir-PC-LR was activated with a freezeethaw cycle
at 80 C and 37 C, which was repeated three times. Then, acti-
vated platelet lysate was centrifuged at 3000  g at 4 C for 30 min
to remove the platelet fragments. The supernatant was filtered
through a 0.22-mm filter unit (Millex-GP; Merck Millipore Ltd.,
Bedford, MA, USA) and 2 U/ml of heparin sodium (5000 units/5 ml;
Mochida Pharmaceutical Co., Tokyo, Japan) was added to prevent
gelatinization. In the present study, this product was referred to as
human platelet lysate (hPL) [8e10].
Next, we prepared three experimental groups. In the first group,
hPL was divided into 3 ml aliquots and stored at 80 C in a deep
freezer for 9 months (C-hPL: the cryopreservation hPL group). In
the second group, hPL cryopreserved for 9 months at 80 C in a
deep freezer then lyophilized using a lyophilize machine (FDU
2200; Tokyo Rikakikai Co, Ltd., Tokyo, Japan) according to the
manufacturer's instructions and reconstituted to the original vol-
ume with saline (Fuso Pharmaceutical Industries, Ltd., Osaka,
Japan) just before use (CL-hPL: the cryopreservation and lyophili-
zation hPL group). In the third group, hPL was snap frozen in liquid
nitrogen and lyophilized using FDU 2200 according to the manu-
facturer's instructions. Lyophilized hPL was refrigerated at 4 C for
9 months and reconstituted to the original volume with saline just
before the experiments (L-hPL: the lyophilization and refrigeration
hPL group).
2.3. The quantitative analysis of the growth factors in preserved hPL
We evaluated the concentrations of three growth factors using
an enzyme-linked immunosorbent assay (ELISA). We used a human
PDGF-BB kit (DBB00), VEGF kit (DVE00) and TGF-b1 (DB100B)
Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA). Ac-
cording to the manufacturer's instructions, for the measurement of
PDGF-BB and VEGF samples require 20-fold dilution before use. For
the measurement of TGF-b1, samples must be acid-activated by 1 N
HCl and neutralized with 1.2 N NaOH/0.5 M HEPES before dilution.
The activated sample is then diluted 400-fold before measurement.
Eight samples were obtained for the PDGF-BB, VEGF and TGF-b1
ELISA evaluations in each group. A total 40 wells was used for each
growth factor, 16 wells (2 rows) were used for standard and 8 wells
(1 row) for each group. Each sample was added to each well of the
provided 96-well plates, which were coated with antibodies prior
to use. They were then incubated, washed and the secondary
antibody was added to the wells. After the addition of the substrate
solution, the optical densities were evaluated at a test wavelength
of 450 nm and a reference wavelength of 540 nm using an Enspire
2300 Multilabel Reader spectrophotometer (PerkinElmer Japan Co.,
Ltd., Yokohama, Japan) to evaluate the concentrations.
2.4. The evaluation of the bioactivity of preserved hPL
We evaluated the bioactivity of preserved hPL in three groups
using a growth assay of fibroblasts. We prepared 1000 ml of DMEM
medium (“Nissui”1; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan)
supplemented with 3.5 g of D(þ) Glucose, 1.8 mg of sodium bicar-
bonate (Wako Pure Chemical Industries Ltd., Osaka, Japan),
10,000 IU of penicillin and 10 mg of streptomycin (Penicillin-
streptomycin; MP Biomedicals, LLC, Solon, OH, USA). We dissemi-
nated 1.0  104 human adult fibroblasts (HDFa; Gibco, Life Tech-
nologies Co., Ltd., Carlsbad, CA, USA) into each well of a 24-well
plate (Iwaki, Asahi Glass Co., Ltd., Tokyo, Japan) and cultured them
using 500 ml of DMEM with 10% FBS (Hyclone, Logan, UT, USA)
overnight at 37 C in a 5% CO2 atmosphere. The next day, we
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changed the medium to 500 ml of DMEM without FBS and incu-
bated the plates overnight. We then changed the medium to
DMEM, DMEMwith 10% FBS, DMEMwith 1% C-hPL, DMEMwith 1%
CL-hPL or DMEMwith 1% L-hPL (n¼ 8 in each group) and incubated
the plates for 48 h. Then, 50 ml of cell counting kit-8 (CCK-8) reagent
(Dojindo Molecular Technologies, Kumamoto, Japan) was added to
each well and the plate was incubated for 60 min. The absorbance
was measured at 450 nm using an Enspire 2300 Multilabel Reader
spectrophotometer (PerkinElmer Japan Co., Ltd., Yokohama, Japan).
2.5. Impregnation of GH disks with hPL
Supplied GH sheets were punched out using a 6-mm punch
biopsy tool (Kai Industries Co., Ltd., Gifu, Japan) to prepare GH disks
of 6mm in diameter. The GH disks were then placed in 10-cm tissue
culture dishes (Falcon, Corning Inc., Corning, NY, USA), and 100 ml of
C-hPL or 100 ml of CL-hPL or 100 ml of L-hPL were dropped onto each
disk (n¼ 21 in each group) using a micropipette and the disks were
incubated overnight at 4 C for impregnation [6,9,23,24].
2.6. Animal wound models
Animal experiment on this study were performed according to
protocols approved by the Animal Care and Use Committee of
Kansai Medical University. Animals received humane care based on
the “Guide for the Care and Use of Laboratory Animals, Eight Edi-
tion,” as published by National Research Council of the National
Academies, 2011. The experiment protocol also approved by the
ethics committee of Kansai Medical University with approval No.
1427. We used 8- to 9-week-old male C57bl6J/Jcl mice (n ¼ 63) as a
wound model to evaluate the effects of hPL in vivo. Prior to surgery,
5 animals were housed per cage in a temperature-controlled ani-
mal facility with a 12-h light/dark cycle. Micewere allowed to adapt
in their environment for one week before the procedure. The ani-
mals had ad libitum access to food and water.
During the procedure, spontaneous breathing mice were anes-
thetized by isoflurane inhalation (Wako Pure Chemical Industries
Ltd., Osaka, Japan) delivered by vaporizer (Forawick vaporizer;
Muraco Medical Co., Ltd., Tokyo, Japan) at a standardized concen-
tration to the outlet tube. Isoflurane was administered in a mixture
with environmental air at a constant flow of 2 l/min. For the in-
duction of anesthesia, animals were placed in a glass box (length,
22 cm; width, 9 cm; height, 11 cm), that was connected to an
anesthetic gas mixture of 3% vaporized isoflurane for 45e60 s. As
maintenance therapy, the concentration of isoflurane was reduced
to 1.5%e2% to provide an appropriate depth of anesthesia during
the surgical procedures.
Before the surgical procedure, the hair on the back of the mouse
was shaved with an electric razor (Thrive; Daito Electric Machine
Ind. Co., Ltd., Japan) and depilated with depilating cream (Kracie,
Tokyo, Japan). A donut-shaped silicone skin splint (Fuji System
Corp., Tokyo, Japan) of 16 mm in outer diameter, 10 mm in inner
diameter, and 0.5 mm in thickness, was attached to the skin with
binding adhesive (Aronalpha; Daiichi Sankyou, Osaka, Japan) and
stitched with black nylon 5e0 (Bear Corporation, Osaka, Japan).
This splintedwoundmodel was used to prevent wound contraction
and delay wound closure [6,25]. Using a punch biopsy tool (Kai
Industries Co., Ltd.) and Iris scissors, a full-thickness wound 6 mm
in diameter including panniculus carnosus was made at the center
of each splint. An GH disk from three groups was put on each
wound (n ¼ 21 in each group). The wound was covered by a
semipermeable polyurethane film (Multifix Roll; Alcare Co., Ltd.,
Tokyo, Japan) and an elastic bandage (Elastopore, Nichiban Co., Ltd.,
Tokyo, Japan) to prevent contamination and damage to thewounds.
After these procedures, the mice were placed in individual cages
inside the institutional animal facility.
2.7. Wound healing evaluation
The mouse wound healing process was evaluated by gross
photos and a histological assessment. Mice were sacrificed by car-
bon dioxide inhalation on days 4, 7, and 14 after surgery (n ¼ 7 in
each group). The dressings were removed and gross photos of the
wound were taken with a digital camera (Olympus Tough TG-4;
Olympus, Tokyo, Japan). Then, the wound specimens including
the surrounding tissue were dissected and fixed in 10% formalin
buffer solution (Wako Pure Chemical Industries, Ltd.) for histolog-
ical staining. The paraffin sections were prepared at the center of
each wound axially and hematoxylin and eosin (HE)-stained sec-
tions, Azan-stained sections, and anti-CD31-stained sections were
prepared. As for the anti-CD31 staining, sections were deparaffi-
nized and rehydrated, and then heat-induced antigen retrieval was
performed in EDTA (Nichirei Biosciences Inc., Tokyo, Japan) at 98 C
for 20 min. After being cooled to room temperature, the sections
were rinsed in distilled water and immersed in 130 mL methanol
(CH3OH; Wako Pure Chemical Industries Ltd.) mixed with 4 mL
hydrogen peroxide (H2O2; Wako Pure Chemical Industries Ltd.) for
10 min to block endogenous peroxidase activity. The sections were
rinsed in TBST (Tris buffered saline with Tween-20; saline with
Tween-20), and rabbit polyclonal antibody (Spring Bioscience,
Fremont, CA, USA) at 1:200 was applied to sections and incubated
at 4 C overnight. The sections were then rinsed in TBST again, after
which HRP-labeled secondary antibody (EnVision þ System HRP-
labeled polymer anti-rabbit; Dako Japan Co., Kyoto, Japan) was
applied at room temperature for 30 min. The sections were rinsed
in TBST again, exposed to DAB (3-30-diaminobenzidine tetrahy-
drochloride; Dako Japan Co., Ltd.), and counterstained with he-
matoxylin. After staining, histologic photographs were taken and
analyzed using a Nanozoomer 2.0 HT whole-slide scanner with the
NDP.view2 software program (Hamamatsu Photonics, Hamamatsu,
Japan) at 40  magnification.
2.8. Assessment of the wound area
The wound area was evaluated by tracing the wound margin on
a digital photograph with the Image J 1.50i software program
(National Institutes of Health, Bethesda, MD, USA). The wound area
was evaluated on days 0, 4, 7 and 14. The remaining wound area (%)
on days 4, 7 and 14 was compared to the original wound area on
day 0 in this study.
2.9. Assessment of neoepithelialization
HE-stained sections were used to evaluate the neo-
epithelialization of each wound on days 4, 7, and 14. The length was
defined as the sum of the lengths of a line traced along the
epithelium from the nearest hair follicle to the forefront of the
neoepithelium at both sides. It is usually difficult to define the
woundmargin onHE sections, soweused the remaining hair follicle
on the marginal wound as the starting point of the neoepithelium.
When wounds were completely epithelized, neoepithelialization
was estimated by tracing the epithelium between the hair follicles
of both sides.
2.10. Assessment of granulation tissue formation
Azan-stained sections were used for the evaluation of granula-
tion tissue formation. On days 4, 7, and 14, the area of granulation
tissue was tracked between the upper new epithelium and the
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lower muscle layer. Besides the area, the thickness of the granula-
tion tissue was also evaluated. The thickness between the upper
and lower border of the granulation tissue was evaluated at three
points: the center of each wound and 500 mm from the wound
center on both sides. The mean of these three measurements was
used for the analysis.
2.11. Assessment of newly formed capillaries and the capillary area
Newly formed capillaries on days 4, 7, and 14 were evaluated
using anti-CD31-stained sections. The numbers and the total area of
newly formed capillaries with a clearly visible lumen and eryth-
rocytes inside were counted manually using the NDP.view2 soft-
ware program. The stained capillaries in three squares of
200 mm  200 mm at the center and both marginal wounds in each
section were counted and the sum was used as the result.
2.12. Statistical analysis
All data are presented as the mean ± standard deviation. P
values of <0.05 were considered to indicate statistical significance.
We used the TukeyeKramer multiple comparisons test, which was
performed using Prism 7.03, to analyze the data (2017; GraphPad
Software, Inc., San Diego, CA, USA).
3. Results
3.1. The comparison of growth factors in the preserved hPL groups
The concentrations of PDGF-BB, VEGF, and TGF-b1 in three
groups are measured by ELISA (Fig. 1AeC). The C-hPL group had
significantly higher concentrations of these growth factors in
comparison to the CL-hPL and L-hPL groups (p < 0.05). The con-
centration of PDGF-BB in the L-hPL group was significantly higher
than that of the CL-hPL group (p < 0.05).
3.2. The evaluation of bioactivity in the preserved hPL groups
Microscopic view of the proliferation of fibroblasts after
culturing for 48 h in all groups were taken (Fig. 2A). The DMEM
with 10% FBS, DMEM with 1% C-hPL, DMEM with 1% CL-hPL, and
DMEM with 1% L-hPL groups showed significantly higher prolifer-
ation in comparison to the DMEM group (p < 0.01). In addition, the
DMEM with 1% CL-hPL group (p < 0.05) and DMEM with 1% L-hPL
group (p < 0.01) showed higher proliferation in comparison to the
DMEM with 10% FBS group (Fig. 2B).
3.3. Assessment of the wound area
The original wound area was 6 mm in diameter on the day of
surgery (Fig. 3A). Gross photos of all three groups on days 4, 7, and
day 14 were taken. The remaining GH disks on the wounds were
observed on days 4 and 7. The wounds were mostly healed by day
14 in all groups (Fig. 3B). No significant differences were observed
in these three groups (Fig. 3C).
3.4. The histological assessment of neoepithelialization
Micrographs of HE-stained sections were evaluated. The neo-
epithelium formed along the wound surface from the wound
margin in all groups. The length of the neoepithelium on days 4, 7
and 14 was similar in all groups. The remaining GH disc was seen in
all groups on days 4 and 7. On day 14, the GH disc had degraded in
all groups (Fig. 4A). A statistical evaluation showed that the length
of the epithelium did not differ among the groups to a statistically
significant extent at any of the time points (Fig. 4B).
3.5. Histological assessment of granulation tissue
Micrographs of Azan-stained sections were used to evaluate the
area and thickness of the granulation tissue that was stained in blue
(Fig. 5A). In Azan-stained sections, the remaining GH disc was
stained in red. The comparison of the area of the granulation tissue
that had formed showed that the granulation area in the CL-hPL
group was significantly larger than that in the L-hPL group on
day 7 (p < 0.05); there were no significant differences among the
groups on other days (Fig. 5B). The granulation tissue thickness did
not differ among the groups at any of the time-points (Fig. 5C).
3.6. Histological assessment of newly formed capillaries
The number and area of the newly formed capillaries detected in
three squares of 200 mm  200 mm at the center and both marginal
Fig. 1. The comparison of the concentrations of (A) PDGF-BB (B) VEGF and (C) TGF-b1
in the three groups. *p < 0.05.
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wounds in each sectionwere counted and the sumwas used for the
analysis (Fig. 6A). Micrographs of anti-CD31-stained sections are
shown in Fig. 6B. Newly formed capillaries were observed starting
from day 4 in all groups. The peak of the neovascularization process
was seen on day 7 in all groups (Fig. 6B). There were no differences
among the groups with regard to the number or area of capillaries
on days 4, 7 and 14 of wound healing (Fig. 6CeD).
4. Discussion
In the present study, we compared the bioactivity of hPL in vitro
and its wound healing effects in vivo after three different preser-
vation methods using a refrigerator or deep freezer for 9 months.
With regard to the bioactivity in vitro, the concentrations of
PDGF-BB, VEGF, and TGF-b1 in the C-hPL group were higher than
those in the groups in which lyophilization was performed (CL-hPL
and L-hPL). The decrease in growth factors in the CL-hPL and L-hPL
groups probably occurred due to the loss of hPL in the lyophiliza-
tion technique. In this process, hPL was powderized, so it was
difficult to collect the powder completely. However, the bioactivity
of the lyophilized hPL in the CL-hPL and L-hPL groups was sufficient
for the proliferation of fibroblasts and the proliferation was
superior to that observed with FBS. This suggests that hPL that had
been refrigerated and lyophilized for 9 months (L-hPL group)
maintained the same degree of bioactivity as cryopreserved hPL (C-
hPL group).
With regard to thewound healing effect, we used GH sheets that
could sustain positively charged growth factors in hPL because we
could compare the healing effects in each group using a single dose
method. The multiple administration of hPL might be affected by
the method of preservation during an animal study. Our results
showed no significant difference in the healing effects (epithelial-
ization, granulation tissue formation and capillary formation)
among the three groups. This suggests the in vivo bioactivity of hPL
that had been refrigerated lyophilized for 9 months (L-hPL group)
was maintained at a level that was similar to that observed in
cryopreserved hPL (C-hPL group).
According to a study by Lai et al. [26], the proliferative effect of
platelet-derivate growth factor cocktail is mainly from PDGF-BB.
The concentrations of PDGF-BB in the C-hPL, CL-hPL and L-hPL
groups were 18,363 ± 370 pg/ml, 11,325 ± 171 pg/ml and
12,307 ± 348 pg/ml respectively. Ito et al. [9] reported that the
concentration of PDGF-BB was 10,000 pg/ml, and our other study
[27] demonstrated that it was 17,432 ± 338 pg/ml. The
Fig. 2. (A) Fibroblast cell proliferation after 48 h of treatment with DMEM, DMEM with 10% FBS, DMEM with 1% C-hPL, or CL-hPL or L-hPL. The three hPL Groups showed higher
proliferation in comparison to the DMEM and DMEM with FBS groups. Scale bar: 500 mm, Original magnification: 40  . (B) The comparison of the proliferation in DMEM, DMEM
with 10% FBS and DMEM with 1% preserved hPL groups. *p < 0.05; **p < 0.01.
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Fig. 3. (A) A macroscopic view of a full-thickness wound of 6 mm in diameter on the day of surgery. The wound margin is indicated by the white broken line. Scale bar: 5 mm. (B) A
macroscopic view of the wound healing process on days 4, 7 and 14 in the C-hPL, CL-hPL and L-hPL groups. Scale bar: 5 mm. (C) The comparison of the remaining wound area on
days 4, 7 and 14.
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concentration of PDGF-BB in this study is in the range of the other
two studies, suggesting that the hPL used in this study was suffi-
cient to promote wound healing. The temperature recommended
for the long-term preservation of growth factors in liquid form is
below 20 C. The other alternative is to make it into a powder
form and preserve it at 4 C. The lyophilization process is a well-
known method for turning a solid product into a powder form,
after which it becomes more stable [18e21]. With regard to the
preservation period, Muraglia A et al. reported that they could
preserve lyophilized platelet-rich plasma for up to 6months [28]. In
the present study, we could preserve the bioactivity of refrigerated
lyophilized hPL for 9 months. The ability to preserve a lyophilized
product at 4 C would be desirable in clinical practice, because the
cost of preserving lyophilized hPL is cheaper in comparison to
cryopreservation using a deep freezer. Although it is difficult to
prepare lyophilized hPL in many hospitals, lyophilized hPL can be
transported more easily than cryopreserved hPL; thus, a processing
facility could support this method of preservation.
Irradiated platelet concentrate, leukocyte reduced (Ir-PC-LR)
provided by Japanese Red Cross Society was used in this study as
the standardized platelet source for making hPL. Regarding the
dispersion of each lot, the Japanese Red Cross Society measured
Fig. 4. (A) Micrographs of HE-stained sections on days 4, 7 and 14. Neoepithelialization was measured above the muscle layer, between hair follicles. Black arrowheads indicate the
hair follicles of the original wound margin. The black broken line indicates the evaluated neoepithelium. Open arrowheads indicate the remaining GH disks. M: muscle, VB:
vertebral bone. Scale bar: 1 mm. (B) The comparison of the length of newly formed epithelium. Data presented in millimeters (mm). There were no significant differences among the
groups.
Fig. 5. (A) Micrographs of Azan-stained sections of wounds on days 4, 7 and 14. Granulation tissue was stained in blue above the muscle layer. The black broken line indicates the
formed granulation tissue. The red double-headed arrow indicates the evaluated thickness of the formed granulation tissue. M: muscle, VB: vertebral bone. Scale bar: 1 mm. (B) The
comparison of the area of formed granulation tissue on days 4, 7 and 14. The granulation tissue of the CL-hPL group was significantly larger than that of the L-hPL group on day 7
(p < 0.05). *p < 0.05. (C) The comparison of the thickness of the formed granulation tissue on days 4, 7 and 14. The thickness of granulation tissue did not differ among the groups.
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several indicators, including the platelet count, pH level, lactate
dehydrogenase percentage and hypotonic shock response of Ir-PC-
LR on the day blood being drawn, and 3, 4, and 5 days later, and
proved that these indicators were stable and similar in every Ir-PC-
LR bag; thus, Ir-PC-LR could be the ideal source of platelets for
regenerative therapy, including wound healing. In Japan, Ir-PC-LR is
only allowed for use for transfusion, and not for other clinical
treatments, such as regenerative therapy. However, we can pur-
chase platelet concentrate for use in regenerative therapy from
foreign companies in the future.
As we showed in the present study, the lyophilization of hPLwas
a preferable preservation method in terms of maintaining its
bioactivity. In addition, we canmanage the concentration of growth
factors in hPL in the reconstitution process [9]. In summary, the
lyophilization of hPL is a superior method for long-term preserva-
tion and would be a versatile method in clinical practice.
5. Conclusions
The quality of human platelet lysate that had been lyophilized
and refrigerated at 4 C was preserved for up to 9 months. This
method may be useful for preserving human platelet lysate for use
in wound treatment in the clinical setting.
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